Darin Okuda, MD

Articles

July 29th 2021

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Key opinion leaders in MS provide closing thoughts on the future of MS treatment including digital therapeutics, new generics, and pipeline drugs on the horizon.

July 29th 2021

Consensus Guidelines for MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Thomas Leist, MD and Darin Okuda, MD describe the current landscape of disease guidelines and algorithms in MS treatment.

July 20th 2021

Disease Progression in MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Experts in MS discuss the challenges related to treatment selection and management when MS disease progression occurs.

July 20th 2021

High Efficacy Therapies in MS: Ocrelizumab, Ofatumumab, and Cladribine

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.

July 15th 2021

Generic First Approach in MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

MS specialists Darin Okuda, MD and Thomas Leist, MD discuss the viability of a generic-first treatment approach in MS.

July 15th 2021

Generic Medications in MS Management

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Key opinion leaders in MS describe the impact of generic medication availability on the management of MS and cost of MS treatment.

July 6th 2021

Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.

July 6th 2021

Evaluation of MS Outcomes: Patient Clinical Picture

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

MS specialist Thomas Leist, MD provides insights into the challenges of evaluating and monitoring patients with MS.

July 1st 2021

Treatment Approach in MS Center of Excellence

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Nancy Ross, PharmD, BCACP, MSCS, CSP describes treatment approach and patient navigation in an MS center of excellence.

July 1st 2021

Payer Management of MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Maria Lopes, MD, MS discusses payer considerations and challenges in MS treatment management with the ongoing paradigm shift toward early high-efficacy treatment.

June 22nd 2021

Selecting First-Line Therapy in MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Thomas Leist, MD and Darin Okuda, MD provide insight into first-line treatment selection for MS and the patient factors involved.

June 22nd 2021

Paradigm Shift in MS Management

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Experts in MS discuss the evolution in treatment options over time and the shift towards use of early high-efficacy therapy.

June 17th 2021

Patient Journey in MS

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

Thomas Leist, MD describes the epidemiology of MS and the journey of patients as the disease progresses.

June 17th 2021

Overview of Multiple Sclerosis

Neil Minkoff, MD Maria Lopes, MD, MS Nancy Ross, PharmD, BCACP, MSCS, CSP Thomas Leist, MD Darin Okuda, MD

A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.